Evidence supporting this includes an enrichment of TF and signaling gene mutations within BMP-like T-ALL blasts (a mutational spectrum shared with myeloid leukemias), non-T lineage marker expression, and shared drug sensitivity profiles with myeloid leukemia stem cells. This evidence concerns the gene TF and acute lymphoblastic leukemia.